{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/glaucoma/prescribing-information/carbonic-anhydrase-inhibitors/","result":{"pageContext":{"chapter":{"id":"9a1dce0a-a42d-5d80-8ded-a8444facf830","slug":"carbonic-anhydrase-inhibitors","fullItemName":"Carbonic anhydrase inhibitors","depth":2,"htmlHeader":"<!-- begin field 56b1ce51-f102-463c-b33e-2fc5f4a1a3b8 --><h2>Carbonic anhydrase inhibitors</h2><!-- end field 56b1ce51-f102-463c-b33e-2fc5f4a1a3b8 -->","summary":"","htmlStringContent":"<!-- begin item 1a6e2e91-b3cd-41c1-94ab-930da3c4429d --><!-- end item 1a6e2e91-b3cd-41c1-94ab-930da3c4429d -->","topic":{"id":"2f2ce020-977b-56c2-bfe0-79af338099b2","topicId":"3f1d1b43-0970-4917-b518-15a04dfd4397","topicName":"Glaucoma","slug":"glaucoma","lastRevised":"Last revised in November 2020","chapters":[{"id":"b70753e1-40bf-5d64-8042-80499a3a3663","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"99932988-c7ac-5201-8a03-324771c52186","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"4665a282-8076-541c-8fdb-d884f514e73a","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"90547efd-385b-5418-95dc-840a239bb4b6","slug":"changes","fullItemName":"Changes"},{"id":"744db240-54ad-5b2b-bde1-fbf5f82dd75c","slug":"update","fullItemName":"Update"}]},{"id":"1b9b2a0b-c1eb-5850-81a4-594deb443996","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d96d012a-8a50-5197-a3bc-80be922d4ec3","slug":"goals","fullItemName":"Goals"},{"id":"ab168d63-48cb-5e39-af87-b20be5416a2b","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"1371aed7-3648-50af-9b62-765d61209340","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"e5d9b1dc-20e2-5c90-807b-c86643d03e27","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"634d007b-489f-5899-be8c-e79e2c12d416","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"895cf400-6256-5dd3-9e84-20a916980e46","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"05123836-33c6-55ab-87b4-82c858ac280b","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"e281b4eb-d1e1-5e3a-ac1e-ba1ce5a60a71","slug":"definition","fullItemName":"Definition"},{"id":"1d1f8e60-4614-5dcc-a66d-9019ca4e6e03","slug":"anatomy-physiology","fullItemName":"Anatomy and physiology"},{"id":"00e7c765-c989-527f-b21f-29ad09409af8","slug":"classification","fullItemName":"Classification"},{"id":"855a9d74-8bb6-54d9-bfc9-5c385ae0f3f4","slug":"causes","fullItemName":"Causes"},{"id":"89456b4f-1b83-5bd6-ba80-018c1171090d","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"37e8081e-c003-5262-a267-bf22817b2d3d","slug":"prevalence","fullItemName":"Prevalence"},{"id":"592dbfb6-31cc-55a6-a38e-b77abbd29565","slug":"prognosis","fullItemName":"Prognosis"},{"id":"f95b1f20-8f4d-5e8f-9e11-426b2a59246a","slug":"complications","fullItemName":"Complications"}]},{"id":"86e2bb04-52a3-5765-8605-aa439e65cf40","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"c3238d06-745f-57aa-b5f9-69dc42896f15","slug":"primary-angle-closure-glaucoma","fullItemName":"Primary angle closure glaucoma"},{"id":"f7c27cd1-50e2-5977-9f46-b1ae6e37f8c6","slug":"ocular-hypertension-primary-open-angle-glaucoma","fullItemName":"Ocular hypertension and primary open angle glaucoma"},{"id":"8f240bf4-5d3c-57ba-a2f7-5e0b82983e5c","slug":"opportunistic-testing-for-glaucoma","fullItemName":"Opportunistic testing for glaucoma"}]},{"id":"c621d247-f521-559a-93ce-c62c3ab5fd2b","fullItemName":"Management","slug":"management","subChapters":[{"id":"1e08cb89-b766-5a2f-9853-4406baa8635c","slug":"acute-angle-closure-angle-closure-glaucoma","fullItemName":"Scenario: Acute angle closure and angle closure glaucoma"},{"id":"803a56e6-2082-5ccc-add9-0d7bd9f32f6a","slug":"primary-open-angle-glaucoma-intraocular-hypertension","fullItemName":"Scenario: Primary open angle glaucoma and intraocular hypertension"}]},{"id":"2d512acb-6e34-566f-8f5f-90eb0d0c8431","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"d784c3ec-391a-5275-a286-56b128e61629","slug":"topical-prostaglandin-analogues-prostamides","fullItemName":"Topical prostaglandin analogues and prostamides"},{"id":"7d644d35-69fa-5a6f-8ceb-fab24019dcee","slug":"topical-beta-blockers","fullItemName":"Topical beta-blockers"},{"id":"7a8c1c4a-8a2d-5555-828d-58b50a740f88","slug":"topical-sympathomimetics","fullItemName":"Topical sympathomimetics"},{"id":"9a1dce0a-a42d-5d80-8ded-a8444facf830","slug":"carbonic-anhydrase-inhibitors","fullItemName":"Carbonic anhydrase inhibitors"},{"id":"efeb705d-eba6-581c-93ad-0916f0aed1c4","slug":"topical-miotics","fullItemName":"Topical miotics"}]},{"id":"657fc5fb-6ac1-5cfe-8fde-6a6eaf21e17b","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"14521c62-39fa-5ea2-9b3b-ba4a79d55565","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"4d0bdf94-c9fe-564d-bd78-4e6e957019c7","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"4dec5995-8a6e-599f-a3ec-4401dda0f2fc","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"fbee715b-cedc-51e6-91f9-00319ab7944f","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"802ad5b9-1cd1-59e9-8b22-2239d0b31c19","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"4211d06e-9a65-51ea-ac4d-d35ca789f223","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"85b73253-be63-5a83-8948-152e3b5a51f7","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"2d512acb-6e34-566f-8f5f-90eb0d0c8431","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"bedd1435-69c0-583d-bbe0-e7cf35fb65df","slug":"available-preparations","fullItemName":"Available preparations","depth":3,"htmlHeader":"<!-- begin field b68d062c-c0a2-440d-9635-3d4a6694230f --><h3>Which carbonic anhydrase inhibitors are available for the treatment of glaucoma?</h3><!-- end field b68d062c-c0a2-440d-9635-3d4a6694230f -->","summary":"","htmlStringContent":"<!-- begin item 9ce020e8-e187-49f3-b89a-1a9b19e24b0d --><!-- begin field 91e73f63-ca34-47f9-974d-aef35b8d0abb --><ul><li><strong>Topical</strong><ul><li>Brinzolamide eye drops. Usual dose is one drop twice daily, increased to three times daily if necessary.</li><li>Dorzolamide hydrochloride eye drops. Usual dose is one drop three times daily.</li><li>Brinzolamide and dorzolomide are also available in combination with timolol. Usual dose is one drop twice daily.</li></ul></li><li><strong>Oral</strong><ul><li>Acetazolamide tablets. Dose is 250 mg to 1 g daily, in divided doses. Modified release capsules are also available. Dose is 250 mg to 500 mg daily.</li></ul></li><li><strong>Parenteral</strong><ul><li>Acetazolamide is also available as an injection for intravenous administration.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">BNF, 2020</a>]</p><!-- end field 91e73f63-ca34-47f9-974d-aef35b8d0abb --><!-- end item 9ce020e8-e187-49f3-b89a-1a9b19e24b0d -->","subChapters":[]},{"id":"efe051f4-eeb6-5370-87e1-e779587e1209","slug":"action","fullItemName":"Action","depth":3,"htmlHeader":"<!-- begin field 0a7de6df-7cae-4667-95b0-34b9e0787477 --><h3>How do carbonic anhydrase inhibitors work?</h3><!-- end field 0a7de6df-7cae-4667-95b0-34b9e0787477 -->","summary":"","htmlStringContent":"<!-- begin item aef6a13c-a94d-4128-ab4f-2eeed6600a5b --><!-- begin field 08031c57-e4a7-42f4-99f1-feefaa1ad092 --><ul><li>Carbonic anhydrase inhibitors reduce intraocular pressure by reducing the secretion of aqueous humour.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">Bowling, 2015</a>]</p><!-- end field 08031c57-e4a7-42f4-99f1-feefaa1ad092 --><!-- end item aef6a13c-a94d-4128-ab4f-2eeed6600a5b -->","subChapters":[]},{"id":"5ea8cad2-aca7-579b-87ff-b0773e947aea","slug":"cautions-contraindications","fullItemName":"Cautions and contraindications","depth":3,"htmlHeader":"<!-- begin field 288e0153-e6e3-42f7-a44e-878b4fbfb96c --><h3>What are the cautions and contraindications when prescribing carbonic anhydrase inhibitors?</h3><!-- end field 288e0153-e6e3-42f7-a44e-878b4fbfb96c -->","summary":"","htmlStringContent":"<!-- begin item ba57f710-16f4-4d9d-8659-6ceb13668968 --><!-- begin field 4dd65614-3db5-4bd9-b92b-0f82ae49630c --><ul><li><strong>Oral acetazolamide is not generally recommended for long-term use. </strong><ul><li><strong>It should not be used in people with: </strong><ul><li>Hypokalaemia. </li><li>Hyponatraemia. </li><li>Severe kidney or liver dysfunction. </li><li>Adrenal gland failure. </li><li>Hyperchloremic acidosis. </li><li>Hypersensitivity to sulphonamides (acetazolamide is a sulphonamide derivative).</li><li>Chronic non-congestive angle closure glaucoma (long-term use is contraindicated as it may permit closure of the angle to occur while the worsening glaucoma is masked by decreased intraocular pressure).</li></ul></li><li><strong>For pregnant women,</strong> the manufacturer advises to avoid.</li><li><strong>Caution is needed</strong> when prescribing to elderly people, and to people with:<ul><li>Pulmonary obstruction and impaired alveolar ventilation (risk of acidosis).</li><li>Diabetes mellitus.</li><li>Renal calculi.</li></ul></li></ul></li><li><strong>Topical brinzolamide.</strong><ul><li><strong>It should not be used in people with:</strong><ul><li>Hyperchloraemic acidosis.</li><li>Sulfonamide hypersensitivity.</li><li>Severe kidney or liver dysfunction.</li></ul></li><li><strong>For pregnant women,</strong> the manufacturer advises to avoid.</li><li><strong>For breastfeeding women,</strong> the manufacturer advises to use only if the benefit outweighs the risk.</li><li><strong>Caution is needed</strong> when prescribing to people with renal tubular immaturity or abnormality.</li></ul></li><li><strong>Topical dorzolamide.</strong><ul><li><strong>It should not be used</strong> in people with:<ul><li>Hyperchloraemic acidosis.</li><li>Sulfonamide hypersensitivity.</li><li>Severe kidney dysfunction.</li></ul></li><li><strong>For pregnant women,</strong> the manufacturer advises to avoid.</li><li><strong>For breastfeeding women,</strong> the manufacturer advises to avoid.</li><li><strong>Caution is needed</strong> when prescribing to people with a history of renal calculi, chronic corneal defects, low endothelial cell count, or a history of intra-ocular surgery.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">ABPI, 2019b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">ABPI, 2020f</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">ABPI, 2020g</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">BNF, 2020</a>]</p><!-- end field 4dd65614-3db5-4bd9-b92b-0f82ae49630c --><!-- end item ba57f710-16f4-4d9d-8659-6ceb13668968 -->","subChapters":[]},{"id":"1e9a23e2-60c0-5b58-9c0d-e62ce46d8f8b","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 8fafdec3-2a1e-4807-88d2-fa0c67aff466 --><h3>What key adverse effects are associated with carbonic anhydrase inhibitors?</h3><!-- end field 8fafdec3-2a1e-4807-88d2-fa0c67aff466 -->","summary":"","htmlStringContent":"<!-- begin item 899c9314-5174-4616-bfce-a946c4456cd9 --><!-- begin field 6b7d1725-8a0c-4abb-9001-6f56bfc9b537 --><ul><li><strong>Key adverse effects associated with topical carbonic anhydrase inhibitors.</strong><ul><li><strong>Local adverse effects</strong><strong> include:</strong><ul><li>Blepharitis.</li><li>Eye irritation, pain, and dryness.</li><li>Blurred vision.</li><li>Lacrimation.</li><li>Allergic reaction to the active drug or preservatives.</li></ul></li><li><strong>Systemic adverse effects</strong><strong> are uncommon</strong> but include:<ul><li>Headache.</li><li>Drowsiness.</li><li>Dizziness.</li><li>Gastrointestinal symptoms such as nausea, vomiting, and dyspepsia.</li><li>Dry mouth and taste disturbances (associated with drainage of the drops into the nasopharynx).</li><li>Stevens-Johnson syndrome.</li></ul></li></ul></li><li><strong>Key adverse effects associated with oral carbonic anhydrase inhibitors.</strong><ul><li><strong>Adverse reactions during short-term use are usually non-serious and include:</strong><ul><li>Tingling feeling in the extremities.</li><li>Loss of appetite or taste disturbance.</li><li>Weight loss.</li><li>Nausea, vomiting, and diarrhoea.</li><li>Polyuria.</li><li>Flushing.</li><li>Thirst.</li><li>Headache.</li><li>Dizziness.</li><li>Fatigue.</li><li>Irritability.</li><li>Depression.</li><li>Kidney stones.</li><li>Stevens-Johnson syndrome.</li><li>Reduced libido.</li><li>Drowsiness and confusion.</li><li>Rarely, photosensitivity has been reported.</li><li>Allergic reaction, including cross-reactivity with sulphonamide antibiotics.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">ABPI, 2019b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">ABPI, 2020f</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">ABPI, 2020g</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">BNF, 2020</a>]</p><!-- end field 6b7d1725-8a0c-4abb-9001-6f56bfc9b537 --><!-- end item 899c9314-5174-4616-bfce-a946c4456cd9 -->","subChapters":[]},{"id":"0e50af9b-2e5c-57bf-9ac9-666107680935","slug":"interactions","fullItemName":"Interactions","depth":3,"htmlHeader":"<!-- begin field b12b8199-4950-4fd4-a01a-ced66ac4ce8d --><h3>What drug interactions are important with carbonic anhydrase inhibitors?</h3><!-- end field b12b8199-4950-4fd4-a01a-ced66ac4ce8d -->","summary":"","htmlStringContent":"<!-- begin item 9eae8922-98ed-4439-a470-53408791b113 --><!-- begin field 1bf0ff9b-5c04-4845-b297-0909d89a01fd --><ul><li><strong>Important drug interactions with topical carbonic anhydrase inhibitors.</strong><ul><li>There are no known important drug interactions with topical carbonic anhydrase inhibitors.</li></ul></li><li><strong>Important drug interactions with oral acetazolamide.</strong><ul><li><strong>Aspirin</strong> — avoid concomitant use with high-dose aspirin and consider prescribing paracetamol or a nonsteroidal anti-inflammatory drug, such as ibuprofen. If indicated, monitor for signs of toxicity, such as confusion, lethargy, hyperventilation, and tinnitus.<ul><li>Concomitant use of acetazolamide and high-dose aspirin can result in metabolic acidosis.</li></ul></li><li><strong>Anticonvulsants,</strong> such as phenytoin, carbamazepine, and phenobarbital — monitor concomitant administration, as acetazolamide can modify the metabolism of some anticonvulsants.<ul><li>Carbamazepine — monitor for signs of carbamazepine toxicity, such as nausea, vomiting, ataxia, and drowsiness. Acetazolamide can cause an increase in serum carbamazepine levels.</li><li>Phenobarbital, phenytoin, and primidone — severe osteomalacia and rickets have been reported in a few people taking phenobarbital, phenytoin, or primidone with acetazolamide.</li></ul></li><li><strong>Ciclosporin </strong>— monitor ciclosporin levels and effects routinely, especially when acetazolamide is initiated or stopped.<ul><li>Acetazolamide can cause a marked and rapid increase in serum ciclosporin levels (up to six-fold in 72 hours). This may be accompanied by renal toxicity.</li></ul></li><li><strong>Lithium </strong>— monitor concurrent administration.<ul><li>Acetazolamide increases lithium excretion and may lead to decreased lithium levels.</li></ul></li><li><strong>Quinidine </strong>— monitor the effects of quinidine if acetazolamide is stopped, and adjust as necessary. Consider monitoring potassium levels to ensure they are within the normal range.<ul><li>Acetazolamide can cause a large increase in urinary pH, leading to quinidine retention and toxicity. Acetazolamide can rarely cause hypokalaemia, which can increase the toxicity of QT-prolonging drugs, such as quinidine.</li></ul></li><li><strong>Other carbonic anhydrase inhibitors</strong> — avoid concomitant use because of possible additive effects.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">ABPI, 2019b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">ABPI, 2020f</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">ABPI, 2020g</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">Preston, 2020</a>]</p><!-- end field 1bf0ff9b-5c04-4845-b297-0909d89a01fd --><!-- end item 9eae8922-98ed-4439-a470-53408791b113 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}